Zest Health, a virtual care company that treats patients with inflammatory skin diseases, announced it raised $14 million in seeding funding. The round was led by Roivant Health, which incubated and ...
The ZEST clinical trial, designed to evaluate niraparib (Zejula) for the prevention of breast cancer recurrence in patients with circulating tumor DNA (ctDNA), failed to accrue enough patients ...
SAN ANTONIO -- A first-in-kind trial of molecular residual disease (MRD)-guided therapy in breast cancer came to an early end because of low randomization, but insights can still be gained on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results